CroíValve is developing the DUO™ Tricuspid Coaptation Valve System, a minimally invasive solution designed for the treatment of severe Tricuspid Regurgitation (TR), which significantly impacts mortality and quality of life in patients over 65. This system uniquely combines repair and replacement techniques to address the specific challenges posed by TR, offering a targeted approach in a growing area of structural heart disease.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MSFounders
Product
Problem
Severe Tricuspid Regurgitation (TR) significantly impacts mortality and quality of life, particularly in patients over 65. This condition presents unique challenges compared to other valvular heart diseases, requiring specifically designed solutions.
Solution
CroíValve is developing the DUO™ Tricuspid Coaptation Valve System, a minimally invasive device designed to treat severe TR. The system uniquely combines repair and replacement techniques to address the specific anatomical and functional challenges posed by TR. By offering a targeted approach, the DUO™ system aims to improve outcomes for patients suffering from this prevalent structural heart condition. The device is intended to provide a best-in-class solution for this unmet clinical need.
Target Audience
The primary target audience includes interventional cardiologists and their patients suffering from severe Tricuspid Regurgitation.
Features
- Minimally invasive delivery system for reduced patient trauma
- DUO™ Coaptation Valve System combines repair and replacement methodologies
- Designed specifically to address the unique challenges of Tricuspid Regurgitation